Abstract
There is a lack of knowledge regarding the effects of estrogens on physical performance. This is related, in part, to the challenge of isolating the effects of estrogens from those of progestins, because levels of both hormones fluctuate across the menstrual cycle, both decline during the menopausal transition, and the administration oh hormones to hypogonadal women typically involves a combination of estrogens and progestins. Some research findings suggest that fluctuations in estrogen levels acutely influence factors that may affect physical performance, such as substrate utilization or maximal aerobic power, but solid evidence is lacking. The simple observation that hypogonadism is not uncommon among elite athletes in some sports suggests that estrogen deficiency does not have a major negative impact on athletic performance. However, chronic hypogonadism may ultimately lead to impaired performance by menas that are not necessarily obvious. For example, chronic estrogen deficiency has potent, deleterious effects on the skeleton that can increase risk for stress fracture and may limit the ability to sustain a high level of physical training. Estrogen deficiency also appears to promote fat accumulation and may accelerate the loss of fat-free mass, and both of these changes in body composition could impair physical performance. There is evidence that hormone replacement attenuates the negative effects of hypogonadism on body composition and bone density, and that effects are mediated primarily by estrogens rather than progestins. Further research is necessary to broaden the understanding of the role of the estrogens in physical performance.
Similar content being viewed by others
References
Braun B, Horton T. Endocrine regulation of exercise substrate utilization in women compared to men. Exerc Sports Sci Rev 2001, 29: 149–54.
Sanborn CF, Horea M, Siemers BJ, Dieringer KI. Disordered eating and the female athlete triad. Clin Sports Med 2000, 19: 199–213.
Lebrun CM, Rumball JS. Relationship between athletic performance and menstrual cycle. Curr Womens Health Rep 2001, 1: 232–40.
Campbell SE, Febbraio MA. Effects of ovarian hormones on exercise metabolism. Curr Opin Clin Nutr Metab Care 2001, 4: 515–20.
Giacomoni M, Bernard T, Gavarry O, Altare S, Falgairette G. Influence of the menstrual cycle phase and menstrua symptoms on maximal anaerobic performance. Med Sci Sports Exerc 2000, 32: 486–92.
Lebrun CM. Effect of the different phases of the menstrual cycle and oral contraceptives on athletic performance. Sports Med 1993, 16: 400–30.
Beals KA, Manore MM. Disorders of the female athlete triad among collegiate athletes. Int J Sport Nutr Exerc Metab 2002, 12: 281–93.
Campbell SE, Angus DJ, Febbraio MA. Glucose kinetics and exercise performance during phases of the menstrua cycle: effect of glucose ingestion. Am J Physiol Endocrinol Metab 2001, 281: E817–25.
Horton TJ, Miller EK, Glueck D, Tench K. No effect of menstrual cycle phase on glucose kinetics and fuel oxidation during moderate-intensity exercise. Am J Physio Endocrinol Metab 2002, 282: E752–62.
Bemben DA, Salm PC, Salm AJ. Ventilatory and blood actate responses to maximal treadmill exercise during the menstrual cycle. J Sports Med Phys Fitness 1995, 35: 257–62.
De Souza MJ, Maguire MS, Rubin KR, Maresh CM. Effects of menstrual phase and amenorrhea on exercise performance in runners. Med Sci Sports Exerc 1990, 22: 575–80.
Lebrun CM, McKenzie DC, Prior JC, Taunton JE. Effects of menstrual cycle phase on athletic performance. Med Sci Sports Exerc 1995, 27: 437–44.
Williams TJ, Krahenbuhl GS. Menstrual cycle phase and running economy. Med Sci Sports Exerc 1997, 29: 1609–18.
Bryner RW, Toffle RC, Ullrich IH, Yeater RA. Effect of low dose oral contraceptives on exercise performance. Br J Sports Med 1996, 30: 36–40.
Casazza GA, Suh SH, Miller BF, Navazio FM, Brooks GA. Effects of oral contraceptives on peak exercise capacity. J Appl Physiol 2002, 93: 1698–702.
Giacomoni M, Falgairette G. Decreased submaximal oxygen uptake during short duration oral contraceptive use: a randomized cross-over trial in premenopausal women. Ergonomics 2000, 43: 1559–70.
Lynch NJ, De Vito G, Nimmo MA. Low dosage monopha-sic oral contraceptive use and intermittent exercise performance and metabolism in humans. Eur J Appl Physio 2001, 84: 296–301.
McCole SD, Brown MD, Moore GE, Zmuda JM, Cwynar JD, Hagberg JM. Cardiovascular hemodynamics with increasing exercise intensities in postmenopausal women. J Appl Physiol 1999, 87: 2334–40.
McCole SD, Brown MD, Moore GE, Zmuda JM, Cwynar JD, Hagberg JM. Enhanced cardiovascular hemodynamics in endurance-trained postmenopausal women athletes. Med Sci Sports Exerc 2000, 32: 1073–9.
Van Pelt RE, Davy KP, Stevenson ET, et al. Smaller differences in total and regional adiposity with age in women who regularly perform endurance exercise. Am J Physiol 1998, 275: E626–34.
Hawkins SA, Marcell TJ, Victoria JS, Wiswell RA. A longitudinal assessment of change in VO2max and maxima heart rate in master athletes. Med Sci Sports Exerc 2001, 33: 1744–50.
Spina RJ, Ogawa T, Kohrt WM, Martin WH, III, Holloszy JO, Ehsani AA. Differences in cardiovascular adaptations to endurance exercise training between older men and women. J Appl Physiol 1993, 75: 849–55.
Spina RJ, Miller TR, Bogenhagen WH, Schechtman KB, Ehsani AA. Gender-related differences in left ventricular filling dynamics in older subjects after endurance exercise training. J Gerontol Biol Sci 1996, 51: B232–7.
Green JS, Stanforth PR, Gagnon J, et al. Menopause, estrogen, and training effects on exercise hemodynamics: the HERITAGE study. Med Sci Sports Exerc 2002, 34: 74–82.
Kohrt WM, Ehsani AA, Birge SJ. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise program. J Appl Physiol 1998, 84: 1506–12.
Evans EM, Van Pelt RE, Binder EF, Williams DB, Ehsani AA, Kohrt WM. Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women. J Appl Physiol 2001, 90: 2033–40.
Nattiv A. Stress fractures and bone health in track and field athletes. J Sci Med Sport 2000, 3: 268–79.
Greendale GA, Barrett-Connor E, Ingles S, Haile R. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 1995, 43: 955–61.
Warren MP, Shantha S. The female athlete. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 37–53.
Gibson JH, Harries M, Mitchell A, Godfrey R, Lunt M, Reeve J. Determinants of bone density and prevalence of osteopenia among female runners in their second to seventh decades of age. Bone 2000, 26: 591–8.
Rencken ML, Chesnut CH III, Drinkwater BL. Bone density at multiple skeletal sites in amenorrheic athletes. JAMA 1996, 276: 238–40.
Buchanan JR, Myers C, LLoyd T, Greer RB, III. Early vertebral trabecular bone loss in normal premenopausal women. J Bone Miner Res 1988, 3: 583–7.
Gulekli B, Davies MC, Jacobs HS. Effect of treatment on established osteoporosis in young women with amenorrhoea. Clin Endocrinol (Oxf) 1994, 41: 275–81.
Drinkwater BL, Bruemmer B, Chesnut CH, III. Menstrua history as a determinant of current bone density in young athletes. JAMA 1990, 263: 545–8.
Keen AD, Drinkwater BL. Irreversible bone loss in former amenorrheic athletes. Osteoporos Int 1997, 7: 311–5.
Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab 2002, 87: 3162–8.
Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001, 98: 576–82.
Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int 2000, 11: 929–37.
Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001, 286: 815–20.
Kohrt WM, Snead DB, Slatopolsky E, Birge SJ Jr. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J Bone Miner Res 1995, 10: 1303–11.
Notelovitz M, Martin D, Tesar R, et al. Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women. J Bone Miner Res 1991, 6: 583–90.
Cumming DC. Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Arch Intern Med 1996, 156: 2193–5.
Cumming DC, Cumming CE. Estrogen replacement therapy and female athletes: current issues. Sports Med 2001, 31: 1025–31.
Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. J Clin Endocrinol Metab 2003, 88: 297–311.
Loucks AB, Verdun M, Heath EM. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 1998, 84: 37–46.
Laughlin GA, Yen SS. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrino Metab 1996, 81: 4301–9.
Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functiona hypothalamic amenorrhea. J Clin Endocrinol Metab 1998, 83: 25–32.
Williams NI, Helmreich DL, Parfitt DB, Caston-Balderrama A, Cameron JL. Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training. J Clin Endocrinol Metab 2001, 86: 5184–93.
Uusi-Rasi K, Sievanen H, Vuori I, Pasanen M, Heinonen A, Oja P. Associations of physical activity and calcium intake with bone mass and size in healthy women at different ages. J Bone Miner Res 1998, 13: 133–142.
Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Int Med 1998, 129: 81–8.
Bassey EJ, Rothwell MC, Littlewood JJ, Pye DW. Pre- and postmenopausal women have different bone mineral density responses to the same high-impact exercise. J Bone Miner Res 1998, 13: 1805–13.
Watts NB. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002, 47: 82–92.
Robling AG, Hinant FM, Burr DB, Turner CH. Improved bone structure and strength after long-term mechanica loading is greatest if loading is separated into short bouts. J Bone Miner Res 2002, 17: 1545–54.
Cheng MZ, Zaman G, Rawlinson SC, Pitsillides AA, Suswillo RF, Lanyon LE. Enhancement by sex hormones of the os-teoregulatory effects of mechanical loading and prostaglandins in explants of rat ulnae. J Bone Miner Res 1997, 12: 1424–30.
Cheng MZ, Zaman G, Rawlinson SC, Suswillo RF, Lanyon LE. Mechanical loading and sex hormone interactions in organ cultures of rat ulna. J Bone Miner Res 1996, 11: 502–11.
Cheng MZ, Rawlinson SC, Pitsillides AA, et al. Human osteoblasts’ proliferative responses to strain and 17ß-estra-diol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res 2002, 17: 593–602.
Joldersma M, Klein-Nulend J, Oleksik AM, Heyligers IC, Burger EH. Estrogen enhances mechanical stress-induced prostaglandin production by bone cells from elderly women. Am J Physiol Endocrinol Metab 2001, 280: E436–42.
Damien E, Price JS, Lanyon LE. The estrogen receptor’s involvement in osteoblasts’ adaptive response to mechanical strain. J Bone Miner Res 1998, 13: 1275–82.
Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Int Med 1995, 123: 673–5.
Douchi T, Kuwahata R, Yamasaki H, et al. Inverse relationship between the changes in trunk lean and fat mass during gonadotropin-releasing hormone agonist therapy. Maturitas 2002, 42: 31–5.
Yamasaki H, Douchi T, Yamamoto S, Oki T, Kuwahata R, Nagata Y. Body fat distribution and body composition during GnRH agonist therapy. Obstet Gynecol 2001, 97: 338–42.
Loucks AB. Physical health of the female athlete: observations, effects, and causes of reproductive disorders. Can J Appl Physiol 2001, 26 (Suppl): S176–85.
Björntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997, 13: 795–803.
Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 2001, 25: 1183–8.
Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 2002, 282: E1023–8.
Gozansky WS, Lindenfeld J. Recognizing coronary artery disease in women. In: Gerhard-Herman M eds. Women’s Health in Primary Care: Aging and Vascular Disease in Women. New York: Jobson Publishing LLC. 2002, 5: 19–27.
Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. JAMA 2003, 349: 523–34.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605–13.
Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20: 291–302.
Lovejoy JC, Bray GA, Bourgeois MO, et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women — a clinical research center study. J Clin Endocrinol Metab 1996, 81: 2198–203.
Davis SR, Walker KZ, Strauss BJG. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 2000, 7: 395–401.
Seeman TE, Singer B, Charpentier P. Gender differences in patterns of HPA axis response to challenge: Macarthur studies of successful aging. Psychoneuroendocrinology 1995, 20: 711–25.
Seeman TE, Singer B, Wilkinson CW, McEwen B. Gender differences in age-related changes in HPA axis reactivity. Psychoneuroendocrinology 2001, 26: 225–40.
Greenspan SL, Rowe JW, Maitland LA, McAloon-Dyke M, Elahi D. The pituitary-adrenal glucocorticoid response is altered by gender and disease. J. Gerontol. 1993, 48: M72–7.
Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 1999, 84: 606–10.
Lindheim SR, Legro RS, Bernstein L, et al. Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 1992, 167: 1831–6.
Kudielka BM, Schmidt-Reinwald AK, Hellhammer DH, Kirschbaum C. Psychological and endocrine responses to psychosocial stress and dexamethasone/cor-ticotropin-releasing hormone in healthy postmenopausa women and young controls: the impact of age and a two-week estradiol treatment. Neuroendocrinology 1999, 70: 422–30.
Tipton KD. Gender differences in protein metabolism. Curr Opin Clin Nutr Metab Care 2001, 4: 493–8.
Aloia JF, McGowan DM, Vaswani AN, Ross P, Cohn SH. Relationship of menopause to skeletal and muscle mass. Am J Clin Nutr 1991, 53: 1378–83.
Wang Q, Hassager C, Ravn P, Wang S, Christiansen C. Total and regional body composition changes in early postmenopausal women: age-related or menopause-re-ated? Am J Clin Nutr 1994, 60: 843–8.
Douchi T, Yamamoto S, Yoshimitsu N, Andoh T, Matsuo T, Nagata Y. Relative contribution of aging and menopause to changes in lean and fat mass in segmental regions. Maturitas 2002, 42: 301–6.
Brown M, Birge SJ Jr, Kohrt WM. Hormone replacement therapy does not augment gains in muscle strength or fat-free mass in response to weight-bearing exercise. J Gerontol Biol Sci 1997, 52A: B166–70.
Tanko LB, Movsesyan L, Svendsen OL, Christiansen C. The effect of hormone replacement therapy on appendicular ean tissue mass in early postmenopausal women. Menopause 2002, 9: 117–21.
Sipila S, Taaffe DR, Cheng S, Puolakka J, Toivanen J, Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in postmenopausal women: a randomized placebo-controlled study. Clin Sci (Lond) 2001, 101: 147–57.
Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993, 84: 95–8.
Skelton DA, Phillips SK, Bruce RA, Naylor CH, Woledge RC. Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausa women. Clin Sci (Colch) 1999, 96: 357–64.
Van Pelt RE, Gozansky WS, Schwartz RS, Kohrt WM. ntravenous estrogens increase insulin clearance and action in postmenopausal women. Am J Physiol Endocrinol Metab 2003, 285; E311–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kohrt, W.M., Van Pelt, R.E. & Gozansky, W.S. Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism. J Endocrinol Invest 26, 902–910 (2003). https://doi.org/10.1007/BF03345242
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345242